Revolution Medicines Officer Exercises and Sells Shares via 10b5-1 Plan
Revolution Medicines, Inc.
Subscribe to track RVMD
Premium users can add ticker alerts and receive realtime notification updates.
Filing Summary
{
"title": "Insider Transaction: Revolution Medicines, Inc. ($RVMD)",
"color": 15158332,
"fields": [
{"name": "Insider", "value": "Anthony Mancini (Chief Global Commercialization Officer)", "inline": false},
{"name": "Transaction", "value": "Sale (Rule 10b5-1)", "inline": true},
{"name": "Shares Sold", "value": "2,310 @ $186.99", "inline": true},
{"name": "Total Value", "value": "$431,946.90", "inline": true},
{"name": "Remaining Shares", "value": "39,765", "inline": true}
]
}
Comprehensive Analysis
Executive Summary
On October 26, 2026, Anthony Mancini, Chief Global Commercialization Officer of Revolution Medicines, Inc. (RVMD), executed a routine option exercise and sale of 2,310 shares of common stock. The transactions were completed under a pre-established Rule 10b5-1 trading plan adopted on June 11, 2026. The shares were sold at a price of $186.99 per share, totaling approximately $431,947 in proceeds.
Transaction Details
- Security: Common Stock
- Option Exercise: 2,310 shares acquired via stock option exercise at an exercise price of $33.62 per share.
- Sale: 2,310 shares sold at $186.99 per share.
- Net Proceeds: ~$354,276.90 (gross proceeds of $431,946.90 less $77,662.20 in exercise cost).
- Holdings Post-Transaction: 39,765 shares directly owned, which includes 39,575 restricted stock units (RSUs).
Market Impact & Significance
This transaction carries Low trading significance as it represents a standard exercise-and-sell pattern conducted under a pre-scheduled Rule 10b5-1 plan, with no discretionary timing by the insider.
Get Real-Time Alerts
Join our community to receive instant notifications when high-significance filings are published
Important Disclaimer
This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.
Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.